Press Releases - 2025-10-08

Date	Title	Company
08-Oct-2025	€28M programme unites universities, charities and industry to deliver next generation cancer care	University College Dublin, Research Ireland and the Department of Further and Higher Education, Research, Innovation and Science
08-Oct-2025	North America Cheese Analogue Market Analysis Report 2025-2032: Vegan and Flexitarian Demand, Precision Fermentation and Foodservice Adoption Drive Growth - ResearchAndMarkets.com	Businesswire
08-Oct-2025	Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29	Businesswire
08-Oct-2025	Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman	Businesswire
08-Oct-2025	VectorBuilder Redefines Plasmid Standards with miniVec	Businesswire
08-Oct-2025	Peek Healthcare Technologies, Inc. ('Peek') Launches Direct-to-Employer and Direct-to-Patient Pricing for IMULDOSA(R) (ustekinumab-srlf) (Stelara(R) Biosimilar)	ACCESS Newswire
08-Oct-2025	Mobility: The New Measure of Aging	ACCESS Newswire
08-Oct-2025	Xenco Medical is Named the Medical Device/Diagnostics Company of the Year at the Prestigious 2025 Trailblazer Awards in New York City	Businesswire
08-Oct-2025	Dr. Jennifer Robinson Calls for Greater Access to Mental Health Care	ACCESS Newswire
08-Oct-2025	Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intramuscular Injections	ACCESS Newswire
08-Oct-2025	Duly Health and Care Physicians Now Offering Access to Galleri(R) Multi-Cancer Early Detection Test	ACCESS Newswire
08-Oct-2025	FairJourney Biologics Appoints Dr. Werner Lanthaler as Chief Executive Officer	Businesswire
08-Oct-2025	Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations	Businesswire
08-Oct-2025	AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors	AlphaMedixTM (212Pb-DOTAMTATE)
08-Oct-2025	AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors	AlphaMedixTM (
08-Oct-2025	Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20	Portzamparc
08-Oct-2025	Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds	Microbot Medical
08-Oct-2025	Medical Care Technologies (OTC PINK:MDCE) Initiates Preparatory Phase for Self-Conducted Research Studies on AI Mental Health and Preventive Biometrics Modules	ACCESS Newswire
08-Oct-2025	Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter	ACCESS Newswire
08-Oct-2025	Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform	Macomics